Poly (ADP-ribose) polymerase (PARP) inhibitors have raised recent excitement because of
the activity reported in triple negative breast cancer (TNBC) with iniparib (BSI 201)[1] and …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted agents for
the treatment of solid tumors. Concurrent PARP inhibition in Breast Cancer Susceptibility …

Inhibitors of poly (ADP-ribose) polymerase (PARP) are considered one of the most active
and exciting new therapies for the treatment of ovarian cancer. The anticancer activity of …

Ovarian cancer is the most lethal gynecologic malignancy in the United States. Some
patients affected by ovarian cancers often present genome instability with one or more of the …

Clinical investigation of poly (ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer
treatment has rapidly evolved from observations of single-agent in vitro activity of these …

Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising activity in epithelial
ovarian cancers, especially relapsed platinum-sensitive high-grade serous disease …

PARP inhibitors represent a major breakthrough in ovarian cancer care. Almost half of all
ovarian cancers have deficiencies in the homologous recombination (HR) DNA repair …

As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and
breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment …

Cancer-specific DNA repair defects are abundant in malignant tissue and present an
opportunity to capitalize on these aberrations for therapeutic benefit. Early preclinical data …

Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs
designed to exploit synthetic lethality, and were first introduced as a cancer-targeting …